Eventide Funds CIO featured in article on Bloomberg.com
Eventide Funds co-founder and fund manager Finny Kuruvilla is the subject of a May 27, 2015 feature published on Bloomberg.com. The article, “Self-Taught Investor Beating Peers With Lesson From Lynch,” focuses on Kuruvilla’s background in medicine and venture capital, and his success in founding and managing Eventide’s two funds part-time until the beginning of 2015, when he made fund management his full-time job.
The article highlights several of Kuruvilla’s most successful stock picks for Eventide’s Gilead and Healthcare and Life Sciences Funds, including NPS Pharmaceuticals, bluebird bio, and Tesla Motors. It also touches on Kuruvilla’s efforts to ensure that Eventide Funds reflects both his expertise and his Christian faith, from the company’s ethical screening process to the theological content of its Faith and Business blog.
Past performance does not guarantee future results.
Mutual Funds involve risk including the possible loss of principal. The fund can invest in smaller- sized companies which may experience higher failure rates than larger companies normally have a lower trading volume than larger companies. The Fund’s ethical values screening criteria could cause it to underperform similar funds that do not have such screening criteria. The fund can have risk associated with the biotechnology and pharmaceutical industry in which these companies may be heavily dependent on clinical trials with uncertain outcomes and decisions made by the U.S. Food and Drug Administration. The fund can have risk related to option investing. There are special risks associated with investments in foreign companies including exposure to currency fluctuations, less efficient trading markets, political instability and differing auditing and legal standards. The fund can have risk associated with a higher portfolio turnover which could result in higher transactional costs.
Investors should carefully consider the investment objectives, risks, charges and expenses of the Eventide Gilead Fund. This and other important information about the Fund is contained in the prospectus, which can be obtained at www.eventidefunds.com or by calling 1-877-771-EVEN (3836). The prospectus should be read carefully before investing. The Eventide Gilead Fund is distributed by Northern Lights Distributors, LLC member FINRA.
4400-NLD-6/15/2015